S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot

BioTelemetry (BEAT) Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.

BEAT vs. AKLI, MODD, DXR, NEPH, FEMY, RVP, CODX, IMAC, MDAI, and ICU

Should you be buying BioTelemetry stock or one of its competitors? The main competitors of BioTelemetry include Akili (AKLI), Modular Medical (MODD), Daxor (DXR), Nephros (NEPH), Femasys (FEMY), Retractable Technologies (RVP), Co-Diagnostics (CODX), IMAC (IMAC), Spectral AI (MDAI), and SeaStar Medical (ICU). These companies are all part of the "medical" sector.

BioTelemetry vs.

Akili (NASDAQ:AKLI) and BioTelemetry (NASDAQ:BEAT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings, profitability and community ranking.

Akili has higher revenue and earnings than BioTelemetry. BioTelemetry is trading at a lower price-to-earnings ratio than Akili, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akili$1.68M16.31-$7.96M-$0.76-0.46
BioTelemetryN/AN/A-$12.96M-$1.24-1.27

BioTelemetry has a net margin of 0.00% compared to BioTelemetry's net margin of -3,545.47%. BioTelemetry's return on equity of -70.96% beat Akili's return on equity.

Company Net Margins Return on Equity Return on Assets
Akili-3,545.47% -70.96% -52.70%
BioTelemetry N/A -140.37%-123.64%

In the previous week, Akili had 14 more articles in the media than BioTelemetry. MarketBeat recorded 16 mentions for Akili and 2 mentions for BioTelemetry. BioTelemetry's average media sentiment score of 0.63 beat Akili's score of 0.00 indicating that Akili is being referred to more favorably in the media.

Company Overall Sentiment
Akili Positive
BioTelemetry Neutral

Akili has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500. Comparatively, BioTelemetry has a beta of -1.37, meaning that its share price is 237% less volatile than the S&P 500.

BioTelemetry received 381 more outperform votes than Akili when rated by MarketBeat users. However, 66.67% of users gave Akili an outperform vote while only 63.86% of users gave BioTelemetry an outperform vote.

CompanyUnderperformOutperform
AkiliOutperform Votes
6
66.67%
Underperform Votes
3
33.33%
BioTelemetryOutperform Votes
387
63.86%
Underperform Votes
219
36.14%

Akili presently has a consensus price target of $4.00, suggesting a potential upside of 1,042.86%. BioTelemetry has a consensus price target of $6.78, suggesting a potential upside of 328.80%. Given BioTelemetry's higher possible upside, research analysts plainly believe Akili is more favorable than BioTelemetry.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akili
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
BioTelemetry
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

53.1% of Akili shares are held by institutional investors. Comparatively, 13.1% of BioTelemetry shares are held by institutional investors. 20.4% of Akili shares are held by company insiders. Comparatively, 7.3% of BioTelemetry shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Akili beats BioTelemetry on 13 of the 15 factors compared between the two stocks.


Get BioTelemetry News Delivered to You Automatically

Sign up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BEAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BEAT vs. The Competition

MetricBioTelemetrySurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$41.60M$3.79B$5.21B$7.62B
Dividend YieldN/A1.88%2.82%3.87%
P/E Ratio-1.2720.74257.1618.81
Price / SalesN/A26.323,095.74110.41
Price / CashN/A26.0699.8655.35
Price / Book5.454.164.534.54
Net Income-$12.96M$19.30M$114.95M$211.55M

BioTelemetry Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AKLI
Akili
3.6706 of 5 stars
$0.47
+2.2%
$4.00
+760.2%
-79.5%$36.41M$320,000.00-0.4266Short Interest ↓
News Coverage
Gap Down
MODD
Modular Medical
3.2416 of 5 stars
$1.66
-3.5%
$4.25
+156.0%
-12.6%$36.35MN/A-1.7137
DXR
Daxor
0 of 5 stars
$7.62
-1.9%
N/AN/A$36.12MN/A0.00N/AShort Interest ↑
NEPH
Nephros
1.5049 of 5 stars
$3.35
-2.9%
N/A+186.1%$35.11M$9.98M0.0027Short Interest ↓
News Coverage
FEMY
Femasys
3.2476 of 5 stars
$1.62
+14.1%
$9.00
+455.6%
+73.1%$35.07M$1.21M-1.6734Short Interest ↓
News Coverage
RVP
Retractable Technologies
0 of 5 stars
$1.29
flat
N/A-34.2%$38.62M$94.82M-3.49190Analyst Report
News Coverage
Gap Down
CODX
Co-Diagnostics
3.5094 of 5 stars
$1.13
+0.9%
$3.00
+165.5%
-61.2%$34.56M$4.66M-0.81145Short Interest ↑
News Coverage
IMAC
IMAC
0 of 5 stars
$1.49
+2.1%
N/A+646.7%$39.46M$15.22M0.00106News Coverage
Gap Up
MDAI
Spectral AI
3.3307 of 5 stars
$1.96
-3.0%
$4.00
+104.1%
N/A$31.85MN/A0.0083Short Interest ↓
News Coverage
ICU
SeaStar Medical
2.7719 of 5 stars
$0.77
-8.3%
$5.00
+547.8%
-72.3%$42.55MN/A0.009Short Interest ↑
Gap Up

Related Companies and Tools

This page (NASDAQ:BEAT) was last updated on 3/3/2024 by MarketBeat.com Staff